Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 3/20 | 0.39 |
| ▸ | LIPG | Q9Y5X9 | 3/20 | 0.39 |
| ▸ | EGFR | P00533 | 2/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.31 |
| ▸ | CA2 | P00918 | 2/20 | 0.31 |
| ▸ | CA9 | Q16790 | 2/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA3 | P07451 | 1/20 | 0.31 |
| ▸ | CA4 | P22748 | 1/20 | 0.31 |
| ▸ | CA6 | P23280 | 1/20 | 0.31 |
| ▸ | CA5A | P35218 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.31 |
| ▸ | F11 | P03951 | 1/20 | 0.30 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.30 |
| ▸ | KDR | P35968 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19950078 | 0.82 | LPL (0.41) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL22833344 | 0.81 | LPL (0.40) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL18152996 | 0.79 | LPL (0.41) | LPLLIPGEGFR | |
| SCHEMBL31042939 | 0.78 | LPL (0.34) | LPLLIPGEGFR | |
| SCHEMBL18797560 | 0.77 | LPL (0.40) | LPLLIPGEGFRCA1CA2 | |
| SCHEMBL20788915 | 0.77 | LPL (0.40) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL29459939 | 0.77 | LPL (0.40) | LPLLIPGCA1CA2CA9 | |
| SCHEMBL24823028 | 0.77 | LPL (0.37) | LPLLIPGEGFRCA1CA2 | |
| SCHEMBL21436489 | 0.76 | LPL (0.39) | LPLLIPGEGFRCA1CA2 | |
| SCHEMBL29837583 | 0.76 | LPL (0.39) | LPLLIPGEGFRCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240083897-A1 | GCN2 MODULATING COMPOUNDS AND USES THEREOF | HIBERCELL, INC. | 2024-03-14 | — | — | US | disclosed |
| EP-4281182-A1 | GCN2 MODULATING COMPOUNDS AND USES THEREOF | Hibercell, Inc. (US) | 2023-11-29 | — | — | EP | disclosed |
| WO-2022159746-A1 | GCN2 MODULATING COMPOUNDS AND USES THEREOF | HIBERCELL, INC. (US) | 2022-07-28 | — | — | WO | disclosed |
| US-8859548-B2 | Compounds and compositions as protein kinase inhibitors | NOVARTIS AG (CH) | 2014-10-14 | — | — | US | disclosed |
| US-8859548-B2 | Compounds and compositions as protein kinase inhibitors | NOVARTIS AG (CH) | 2014-10-14 | — | — | US | disclosed |
| EP-2470528-B1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | NOVARTIS AG (CH) | 2014-10-01 | — | — | EP | disclosed |
| EP-2470528-B1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | NOVARTIS AG (CH) | 2014-10-01 | — | — | EP | disclosed |
| US-20140011825-A1 | Compounds and Compositions as Protein Kinase Inhibitors | NOVARTIS AG (CH) | 2014-01-09 | — | — | US | disclosed |
| US-20140011825-A1 | Compounds and Compositions as Protein Kinase Inhibitors | NOVARTIS AG (CH) | 2014-01-09 | — | — | US | disclosed |
| US-8563553-B2 | Compounds and compositions as protein kinase inhibitors | NOVARTIS AG (CH) | 2013-10-22 | — | — | US | disclosed |
| US-20120225899-A1 | Compounds and Compositions as Protein Kinase Inhibitors | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2012-09-06 | — | — | US | disclosed |
| US-20120225899-A1 | Compounds and Compositions as Protein Kinase Inhibitors | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2012-09-06 | — | — | US | disclosed |
| US-20120225899-A1 | Compounds and Compositions as Protein Kinase Inhibitors | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2012-09-06 | — | — | US | disclosed |
| US-8242260-B2 | Compounds and compositions as protein kinase inhibitors | NOVARTIS AG (CH) | 2012-08-14 | — | — | US | disclosed |
| US-8242260-B2 | Compounds and compositions as protein kinase inhibitors | NOVARTIS AG (CH) | 2012-08-14 | — | — | US | disclosed |
| US-8242260-B2 | Compounds and compositions as protein kinase inhibitors | NOVARTIS AG (CH) | 2012-08-14 | — | — | US | disclosed |
| WO-2011023773-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | NOVARTIS AG (CH) | 2011-03-03 | — | — | WO | disclosed |
| US-20110052578-A1 | Compounds and Compositions as Protein Kinase Inhibitors | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2011-03-03 | — | — | US | disclosed |
| US-20110052578-A1 | Compounds and Compositions as Protein Kinase Inhibitors | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2011-03-03 | — | — | US | disclosed |
| US-20110052578-A1 | Compounds and Compositions as Protein Kinase Inhibitors | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2011-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110052578-A1 | Compounds and Compositions as Protein Kinase Inhibitors | RAF1, BRAF, ARAF | LPL 3486/4885LIPG 2585/4885EGFR 177/4885 |
| US-20240083897-A1 | GCN2 MODULATING COMPOUNDS AND USES THEREOF | EIF2AK4, GCN1, CLN6 | LPL 938/4885LIPG 1811/4885EGFR 4343/4885 |
| US-20120225899-A1 | Compounds and Compositions as Protein Kinase Inhibitors | RAF1, BRAF, ARAF | LPL 3486/4885LIPG 2585/4885EGFR 177/4885 |
| US-20140011825-A1 | Compounds and Compositions as Protein Kinase Inhibitors | RAF1, BRAF, ARAF | LPL 3486/4885LIPG 2585/4885EGFR 177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.